Does preterm birth influence the response to growth hormone treatment in short, small for gestational age children?

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Neonatal Development

Background:

• Small for gestational age (SGA) is a common condition in newborns.
• Prematurity is often associated with SGA, but its independent effect on growth and treatment response is unclear.
• Understanding these factors is crucial for optimizing growth hormone (GH) therapy.

Purpose of the Study:

• To determine if prematurity independently influences the response to GH treatment in short SGA children.
• To compare growth parameters and GH treatment outcomes between preterm and term SGA children.

Main Methods:

• A 3-year longitudinal study involving 392 prepubertal, non-GH-deficient, short SGA children (138 preterm, 254 term).
• Measurements included height, weight, head circumference, skinfolds, and serum IGF-I and IGFBP-3 levels.
• Data were collected at baseline and at 6 months, 1, 2, and 3 years of GH treatment.

Main Results:

• Preterm SGA children were significantly smaller and leaner at birth and at the start of GH treatment compared to term SGA children.
• Prematurity did not affect childhood IGF-I and IGFBP-3 levels.
• The response to GH treatment was comparable between preterm and term SGA children.

Conclusions:

• Prematurity is associated with a smaller size for gestational age and a leaner phenotype in short SGA children.
• Despite initial size differences, prematurity does not alter the efficacy of GH treatment in this population.
• GH therapy provides similar growth benefits for both preterm and term short SGA children.